Xenetic Biosciences, Inc.XBIONASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank64
5Y CAGR-29.3%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-29.3%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 15.22% |
| Q2 2025 | -25.31% |
| Q1 2025 | -15.66% |
| Q4 2024 | 183.23% |
| Q3 2024 | -60.59% |
| Q2 2024 | -1.12% |
| Q1 2024 | -3.21% |
| Q4 2023 | -4.41% |
| Q3 2023 | 12.99% |
| Q2 2023 | 51.74% |
| Q1 2023 | -64.61% |
| Q4 2022 | 321.73% |
| Q3 2022 | -80.80% |
| Q2 2022 | 88.62% |
| Q1 2022 | -10.39% |
| Q4 2021 | 57.54% |
| Q3 2021 | 48.73% |
| Q2 2021 | -16.70% |
| Q1 2021 | 28.31% |
| Q4 2020 | -14.36% |
| Q3 2020 | 86.12% |
| Q2 2020 | -14.39% |
| Q1 2020 | -13.84% |
| Q4 2019 | -88.14% |
| Q3 2019 | 622.15% |
| Q2 2019 | 5.12% |
| Q1 2019 | -9.90% |
| Q4 2018 | -30.05% |
| Q3 2018 | -20.62% |
| Q2 2018 | 31.26% |
| Q1 2018 | -34.62% |
| Q4 2017 | 22.09% |
| Q3 2017 | -5.16% |
| Q2 2017 | -23.60% |
| Q1 2017 | 71.63% |
| Q4 2016 | -20.22% |
| Q3 2016 | -97.86% |
| Q2 2016 | 9615.13% |
| Q1 2016 | -58.20% |
| Q4 2015 | 25.79% |